Citizens Jmp Reaffirms “Market Outperform” Rating for Intellia Therapeutics (NASDAQ:NTLA)

Intellia Therapeutics (NASDAQ:NTLA)‘s stock had its “market outperform” rating reaffirmed by Citizens Jmp in a report released on Wednesday, Benzinga reports. They currently have a $30.00 price objective on the stock. Citizens Jmp’s target price would indicate a potential upside of 135.48% from the stock’s current price.

Several other research analysts have also recently issued reports on the company. Sanford C. Bernstein upped their price objective on Intellia Therapeutics from $13.00 to $17.00 and gave the stock a “market perform” rating in a research report on Wednesday, May 13th. Wall Street Zen downgraded shares of Intellia Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 8th. Wolfe Research downgraded shares of Intellia Therapeutics from a “peer perform” rating to an “underperform” rating and set a $9.00 target price on the stock. in a research report on Wednesday, July 15th. HC Wainwright reissued a “buy” rating and issued a $25.00 target price on shares of Intellia Therapeutics in a report on Wednesday. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Intellia Therapeutics in a research note on Tuesday, August 25th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, eight have issued a Hold rating and four have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $20.98.

Intellia Therapeutics Price Performance

NASDAQ:NTLA opened at $12.74 on Wednesday. Intellia Therapeutics has a 52 week low of $7.95 and a 52 week high of $28.25. The company has a fifty day simple moving average of $12.78 and a two-hundred day simple moving average of $13.42. The company has a market cap of $1.79 billion, a price-to-earnings ratio of -3.79 and a beta of 1.82.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.80) earnings per share for the quarter, hitting the consensus estimate of ($0.80). Intellia Therapeutics had a negative return on equity of 57.79% and a negative net margin of 672.16%.The company had revenue of $7.66 million for the quarter, compared to the consensus estimate of $12.98 million. During the same quarter in the prior year, the business earned ($0.98) EPS. Intellia Therapeutics’s revenue was down 46.4% on a year-over-year basis. On average, analysts expect that Intellia Therapeutics will post -3.21 EPS for the current year.

Insider Transactions at Intellia Therapeutics

In other news, EVP J III sold 4,677 shares of the firm’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $18.00, for a total transaction of $84,186.00. Following the completion of the transaction, the executive vice president owned 156,286 shares in the company, valued at approximately $2,813,148. This trade represents a 2.91% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CAO Michael Dube sold 2,641 shares of the stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $16.78, for a total value of $44,315.98. Following the sale, the chief accounting officer owned 66,886 shares of the company’s stock, valued at $1,122,347.08. This trade represents a 3.80% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 3.50% of the stock is owned by insiders.

Institutional Investors Weigh In On Intellia Therapeutics

Hedge funds have recently modified their holdings of the business. Caitong International Asset Management Co. Ltd acquired a new stake in Intellia Therapeutics in the 3rd quarter worth $30,000. Advisory Services Network LLC bought a new position in Intellia Therapeutics in the 3rd quarter worth approximately $33,000. Nykredit A S acquired a new position in Intellia Therapeutics during the 2nd quarter valued at about $33,000. Freestone Grove Partners LP acquired a new position in shares of Intellia Therapeutics in the 2nd quarter valued at $33,000. Finally, Integrated Wealth Concepts LLC bought a new position in Intellia Therapeutics during the second quarter worth about $34,000. 88.77% of the stock is owned by institutional investors.

Intellia Therapeutics News Roundup

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: The FDA granted Priority Review to Intellia’s biologics license application for lonvo-z and set a PDUFA decision date of March 10, 2027. If approved, lonvo-z could become the first in vivo CRISPR-based therapy and the only one-time treatment for HAE, offering substantial commercial differentiation. Intellia FDA acceptance announcement
• Positive Sentiment: HC Wainwright reaffirmed its Buy rating and assigned a $25 price target, implying substantial potential upside from the stock’s recent $12.74 level. The target reflects optimism about lonvo-z and Intellia’s CRISPR platform. Benzinga analyst report
• Neutral Sentiment: Wedbush raised its price target to $13 from $12 but maintained a Neutral rating. The revised target indicates only limited near-term valuation upside and shows that analysts remain cautious despite the FDA milestone. Wedbush Intellia price target update
• Neutral Sentiment: Intellia was highlighted among genomics companies attracting investor interest in 2026, reinforcing broader enthusiasm for gene-editing and precision-medicine technologies, but the article did not announce a new company-specific development. Zacks genomics stocks article

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.